The stock closed at ₹1,788.00, down 1.47% from the previous close of ₹1,814.60, with intraday prices ranging between ₹1,786.00 and ₹1,822.05. Over the past week, Gland Pharma’s stock return was -3.31%, contrasting with the Sensex’s 0.96% gain. The one-month return showed a decline of 7.63%, while the Sensex recorded a modest 0.86% rise. Year-to-date, the stock’s return was nearly flat at -0.03%, compared to the Sensex’s 8.36% increase. Over longer horizons, the stock’s returns remain subdued relative to the benchmark, with a 1-year return of 0.79% against Sensex’s 9.48%, and a 3-year return of 2.84% versus Sensex’s 37.31%.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- Early turnaround signals
- Explosive growth potential
- Textile - Machinery recovery play
Position for Explosive Growth →
Examining the technical indicators, the weekly and monthly MACD readings both indicate a mildly bearish stance, signalling a potential weakening in upward momentum. The Relative Strength Index (RSI) on weekly and monthly charts currently shows no definitive signal, suggesting a neutral momentum without clear overbought or oversold conditions. Bollinger Bands present a mixed scenario: weekly data points to a bearish trend, while monthly readings suggest a mildly bullish outlook, reflecting some volatility in price movements.
Moving averages on the daily timeframe maintain a mildly bullish posture, indicating short-term support for the stock price. However, the KST (Know Sure Thing) indicator aligns with the MACD, showing mildly bearish trends on both weekly and monthly scales. Dow Theory analysis reveals no clear trend on the weekly chart but a mildly bearish indication monthly, reinforcing the cautious technical environment. On-Balance Volume (OBV) also reflects mildly bearish signals across weekly and monthly periods, hinting at volume trends that may not support strong price advances.
Gland Pharma or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- SwitchER analysis complete
- Superior alternatives found
- Multi-parameter evaluation
Gland Pharma’s market capitalisation grade stands at 3, reflecting its mid-tier position within the Pharmaceuticals & Biotechnology sector. The recent adjustment in its evaluation score, effective from 19 Nov 2025, follows a revision in technical parameters that have shifted the overall trend from mildly bullish to mildly bearish. This change underscores the importance of monitoring technical momentum alongside fundamental factors for a comprehensive view of the stock’s outlook.
Investors should note the stock’s 52-week high of ₹2,130.00 and low of ₹1,200.00, highlighting a wide trading range over the past year. The current price level near ₹1,788.00 situates the stock closer to the upper half of this range, though recent price momentum suggests caution. The divergence between short-term bullish moving averages and broader bearish signals from MACD and KST indicates a complex technical environment requiring close observation.
In comparison to the broader market, Gland Pharma’s returns have lagged behind the Sensex across most timeframes, particularly over the medium term. This relative underperformance, combined with mixed technical signals, suggests that the stock is undergoing a phase of consolidation or adjustment in momentum. Market participants may find value in analysing these technical parameters in conjunction with sectoral trends and company fundamentals to inform their investment decisions.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
